$24.42
1.93% yesterday
Nasdaq, Sep 24, 10:00 pm CET
ISIN
NL00150005Y4
Symbol
PHVS

Pharvaris NV Stock price

$24.42
+0.77 3.26% 1M
+8.95 57.85% 6M
+5.25 27.39% YTD
+5.43 28.59% 1Y
+16.47 207.21% 3Y
+4.42 22.10% 5Y
+4.42 22.10% 10Y
+4.42 22.10% 20Y
Nasdaq, Closing price Wed, Sep 24 2025
-0.48 1.93%
ISIN
NL00150005Y4
Symbol
PHVS
Industry

Key metrics

Basic
Market capitalization
$1.6b
Enterprise Value
$1.3b
Net debt
positive
Cash
$234.3m
Shares outstanding
54.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
7.2
Financial Health
Equity Ratio
91.9%
Return on Equity
-50.1%
ROCE
-89.6%
ROIC
-3,492.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-193.9m | $-205.9m
EBIT
$-194.3m | $-202.5m
Net Income
$-197.6m | $-184.5m
Free Cash Flow
$-161.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-42.7% | -20.6%
EBIT
-42.6% | -18.4%
Net Income
-47.5% | -17.1%
Free Cash Flow
-38.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.6
FCF per Share
$-2.9
Short interest
0.8%
Employees
114
Rev per Employee
$0.0
Show more

Is Pharvaris NV a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Pharvaris NV Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Pharvaris NV forecast:

15x Buy
88%
1x Hold
6%
1x Sell
6%

Analyst Opinions

17 Analysts have issued a Pharvaris NV forecast:

Buy
88%
Hold
6%
Sell
6%

Financial data from Pharvaris NV

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 56 56
29% 29%
-
- Research and Development Expense 138 138
49% 49%
-
-194 -194
43% 43%
-
- Depreciation and Amortization 0.40 0.40
25% 25%
-
EBIT (Operating Income) EBIT -194 -194
43% 43%
-
Net Profit -198 -198
47% 47%
-

In millions USD.

Don't miss a Thing! We will send you all news about Pharvaris NV directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pharvaris NV Stock News

Neutral
Seeking Alpha
15 days ago
Pharvaris N.V. (NASDAQ:PHVS ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 8:30 AM EDT Company Participants Berndt A.
Neutral
Seeking Alpha
20 days ago
Pharvaris N.V. (NASDAQ:PHVS ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 3:45 PM EDT Company Participants Peng Lu - Chief Medical Officer Conference Call Participants Tiago Fauth - Wells Fargo Securities, LLC, Research Division Presentation Tiago Fauth Equity Analyst My name is Tiago Fauth.
Neutral
Seeking Alpha
21 days ago
Pharvaris N.V. (NASDAQ:PHVS ) Cantor Global Healthcare Conference 2025 September 3, 2025 11:30 AM EDT Company Participants Wim Souverijns - Chief Commercial Officer Peng Lu - Chief Medical Officer Conference Call Participants Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Presentation Steven Seedhouse MD & Biotechnology Analyst Okay.
More Pharvaris NV News

Company Profile

Pharvaris NV is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Hans G. C. P. Schikan and Anne Lesage on September 30, 2015 and is headquartered in Leiden, Netherlands.

Head office Netherlands
CEO Berndt Modig
Employees 114
Founded 2015
Website pharvaris.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today